EFFECT OF DRUG NISHAMLAKI IN PCOS
Not Applicable
Completed
- Conditions
- Health Condition 1: null- polycystic ovarian syndromeHealth Condition 2: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2017/07/009111
- Lead Sponsor
- Pharmaza Herbals Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
females diagnosed with polycystic ovarian syndrome
Exclusion Criteria
patients with
1.known liver,kidney,heart disease
2.complaining of infertility
3.active infection such as HIV, tuberculosis,hepatitis,etc
4.assosiated cervical and/or uterine pathologies like fibroid,polyp, endometriosis,etc
5.congenital anamolies related to genital tract
6.other endocrinal abnormalities
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Nishamlaki's efficacy in treating polycystic ovarian syndrome (E282)?
How does Nishamlaki compare to metformin in managing insulin resistance and hormonal imbalances in PCOS patients?
What biomarkers correlate with Nishamlaki's efficacy in CTRI/2017/07/009111 for polycystic ovarian syndrome (E282)?
What are the safety profiles and adverse event management strategies for Nishamlaki in PCOS treatment?
Are there combination therapies involving Nishamlaki and other herbal compounds for polycystic ovarian syndrome (E282)?